OncoAlert and ecancer ASCO roundup - Day 3

OncoAlert and ecancer ASCO roundup - Day 2

OncoAlert and ecancer ASCO roundup - Day 1

Amivantamab in combination with lazertinib for osimertinib-relapsed, chemo-naïve EGFRm NSCLC

NIVO plus chemo vs chemo alone as neoadjuvant treatment for patients with resectable NSCLC

Nivolumab plus ipilimumab or NIVO plus chemo versus chemo as firstline for advanced ESCC

KEYNOTE-564: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma

RELATIVITY-047: Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer

SEMS trial: result of a prospective, multi-institutional phase II clinical trial of surgery in early metastatic seminoma

Current treatment standards for primary ovarian cancer

Evolving medical treatment in advanced/recurrent endometrial cancer